Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex for spasticity in multiple sclerosis
NCT01868048Phase 3Withdrawn
- Sponsor
- GW Pharmaceuticals
- Primary completion
- Jun 2017
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of cannabidiol in spasticity, sponsored by GW Pharmaceuticals. Status: withdrawn.
02
Drugs
cannabidiol
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT01868048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01868048.